Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE refuses cancer drugs Arzerra, Torisel and Levact

October 27, 2010
Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs

NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …

News

£600m confirmed for three year Cancer Drugs Fund

October 27, 2010
Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing

The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …

News

Minister confirms NICE will be sidelined in drug evaluation

October 26, 2010
Sales and Marketing Andrew Lansley, Lord Howe, NICE, PPRS, medicines pricing, value-based pricing

A health minister has confirmed NICE will be “moved” from its current central role in health technology assessment to make …

News
Pharma association the ABPI

NICE needs narrower focus, says ABPI

October 20, 2010
Sales and Marketing ABPI, NICE, value

NICE’s remit should be changed to give it a greater focus on the value of innovation, according to UK pharma …

News

NICE rejects GSK Tyverb appeal

October 14, 2010
Sales and Marketing GlaxoSmithKline, NICE, Tyverb

NICE’s independent appeal board has ruled the UK drug’s watchdog did not exceed its powers when issuing guidance on GlaxoSmithKline’s …

News

NICE unmoved on Takeda bone cancer drug

October 13, 2010
Sales and Marketing Mepact, NICE, Takeda

NICE has refused to recommend Takeda’s Mepact because of its “exceptionally high cost” and the “substantial uncertainty” about the osteosarcoma …

News

Battle for Alzheimer’s drugs finally over

October 8, 2010
Sales and Marketing Alzheimer's, Aricept, NICE

NICE is to allow wider access to Alzheimer’s disease treatments, ending an epic five year battle for access to the …

News

NICE announces change of heart on Alzheimer’s

October 7, 2010
Sales and Marketing Alzheimer's, Aricept, Ebixa, Exelon, NICE, Reminyl

NICE is set to update its guidance on treatments for Alzheimer´s disease, widening access to four drugs. The draft guidance …

News

National Institute for health and Clinical Excellence (NICE)

October 1, 2010
NICE, National Institute for health and Clinical Excellence

The National Institute for health and Clinical Excellence (NICE) is a UK cost-effectiveness body that assesses a drug’s cost against …

News
Herceptin packs

New Herceptin data sways NICE

September 30, 2010
Sales and Marketing Herceptin, NICE, Roche

NICE is now minded to approve Roche’s Herceptin for patients with metastatic gastric cancer after receiving new efficacy data from …

News

Pay people to be healthy, say NICE advisors

September 28, 2010
NHS, NICE, public health

The NHS should use financial incentives to encourage people to make healthier lifestyle changes, according to NICE’s Citizen’s Council. The …

News

GSK’s leukaemia drug rejected by NICE

September 16, 2010
Sales and Marketing Arzerra, GSK, NHS, NICE

GSK’s leukaemia treatment Arzerra has been rejected by NICE, which says the drug does not represent good value for the …

News

NICE won’t approve Abilify without more data

September 13, 2010
Sales and Marketing Abilify, BMS, NICE

NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …

News
Novo Nordisk's Victoza

Low dose Victoza on track for NICE approval

September 10, 2010
Sales and Marketing NICE, Novo Nordisk, Victoza

Novo Nordisk is on track to receive NICE approval for its type II diabetes drug Victoza, but will still have …

News
Velcade

Janssen to appeal against Velcade decision

August 26, 2010
Medical Communications, Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s Thalidomide has been recommended by NICE for multiple myeloma ahead of Janssen-Cilag’s Velcade. A final appraisal determination says that …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026